Compare Stocks: DSGN, AMLX, ZLAB, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$28.14 +3.5%	$30.42	$10.83 ▼ $41.14	$3.14B	-0.1	1.50 million shs	1.47 million shs
DSGN Design Therapeutics	$11.65 +1.4%	$13.83	$5.28 ▼ $17.25	$729.08M	1.68	748,639 shs	356,593 shs
DYN Dyne Therapeutics	$16.64 +1.6%	$21.56	$13.73 ▼ $27.31	$3.11B	1.12	3.33 million shs	3.57 million shs
ZLAB Zai Lab	$24.99 +0.7%	$25.03	$15.96 ▼ $32.76	$2.84B	0.73	818,382 shs	1.02 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+1.26%	-12.31%	+58.36%	+108.75%
DSGN Design Therapeutics	0.00%	-5.59%	-21.28%	-23.30%	+67.87%
DYN Dyne Therapeutics	0.00%	+9.47%	-9.66%	-28.95%	+14.29%
ZLAB Zai Lab	0.00%	+2.71%	+3.39%	+21.96%	-25.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$28.14 +3.5%	$30.42	$10.83 ▼ $41.14	$3.14B	-0.1	1.50 million shs	1.47 million shs
DSGN Design Therapeutics	$11.65 +1.4%	$13.83	$5.28 ▼ $17.25	$729.08M	1.68	748,639 shs	356,593 shs
DYN Dyne Therapeutics	$16.64 +1.6%	$21.56	$13.73 ▼ $27.31	$3.11B	1.12	3.33 million shs	3.57 million shs
ZLAB Zai Lab	$24.99 +0.7%	$25.03	$15.96 ▼ $32.76	$2.84B	0.73	818,382 shs	1.02 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+1.26%	-12.31%	+58.36%	+108.75%
DSGN Design Therapeutics	0.00%	-5.59%	-21.28%	-23.30%	+67.87%
DYN Dyne Therapeutics	0.00%	+9.47%	-9.66%	-28.95%	+14.29%
ZLAB Zai Lab	0.00%	+2.71%	+3.39%	+21.96%	-25.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$38.86	38.09% Upside
DSGN Design Therapeutics	2.89	Moderate Buy	$17.86	53.28% Upside
DYN Dyne Therapeutics	2.82	Moderate Buy	$33.07	98.75% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	49.06% Upside

Current Analyst Ratings Breakdown

Latest DSGN, AMLX, ZLAB, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/2/2026	DSGN Design Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
10/2/2026	DSGN Design Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
9/30/2026	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$37.00
9/30/2026	DYN Dyne Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/30/2026	DYN Dyne Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
9/30/2026	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$38.00
9/30/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $32.00
9/29/2026	DYN Dyne Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$47.00
9/9/2026	DYN Dyne Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$45.00 ➝ $36.00
9/9/2026	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $26.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	35.89	N/A	N/A	$2.78 per share	10.12
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
ZLAB Zai Lab	$460.16M	6.18	N/A	N/A	$6.39 per share	3.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest DSGN, AMLX, ZLAB, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AMLX Amylyx Pharmaceuticals	-$0.3831	N/A	N/A	N/A	$0.06 million	N/A
11/5/2026	Q3 2026	ZLAB Zai Lab	-$0.5642	N/A	N/A	N/A	$108.84 million	N/A
11/4/2026	Q3 2026	DSGN Design Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	DYN Dyne Therapeutics	-$0.9122	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
7/29/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
DSGN Design Therapeutics	N/A	18.86	18.86
DYN Dyne Therapeutics	0.28	12.02	12.02
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
DSGN Design Therapeutics	56.64%
DYN Dyne Therapeutics	96.68%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
DSGN Design Therapeutics	17.10%
DYN Dyne Therapeutics	9.46%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

DSGN, AMLX, ZLAB, and DYN Headlines

Recent News About These Companies

Zai Lab stock closed at USD 25.58 before ESMO data

October 7, 2026 | ad-hoc-news.deA

Critical Comparison: Zai Lab (NASDAQ:ZLAB) vs. Anixa Biosciences (NASDAQ:ANIX)

October 7, 2026 | americanbankingnews.com

Zai Lab stock faces a key ESMO test after Cantor target call

October 7, 2026 | ad-hoc-news.deA

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's Why

October 6, 2026 | marketbeat.com

Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?

October 4, 2026 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6% - Here's Why

October 2, 2026 | marketbeat.com

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

September 29, 2026 | marketscreener.comM

Zai Lab (NASDAQ:ZLAB) Stock Jumps 3.8% - What's Next?

September 28, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Raised to "Hold" at Wall Street Zen

September 26, 2026 | marketbeat.com

Zai Lab Ltd (ZLAB)

September 24, 2026 | in.investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2026 | marketbeat.com

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DSGN, AMLX, ZLAB, and DYN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$28.14 +0.94 (+3.46%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$28.13 -0.01 (-0.04%)

As of 10/9/2026 07:34 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Design Therapeutics NASDAQ:DSGN

$11.65 +0.16 (+1.39%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.65 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Dyne Therapeutics NASDAQ:DYN

$16.64 +0.27 (+1.65%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$16.53 -0.11 (-0.67%)

As of 10/9/2026 07:55 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Zai Lab NASDAQ:ZLAB

$24.99 +0.18 (+0.73%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$24.58 -0.41 (-1.66%)

As of 10/9/2026 07:30 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, AMLX, ZLAB, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, AMLX, ZLAB, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, AMLX, ZLAB, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DSGN, AMLX, ZLAB, and DYN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Design Therapeutics NASDAQ:DSGN

Dyne Therapeutics NASDAQ:DYN

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, AMLX, ZLAB, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, AMLX, ZLAB, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, AMLX, ZLAB, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DSGN, AMLX, ZLAB, and DYN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Design Therapeutics NASDAQ:DSGN

Dyne Therapeutics NASDAQ:DYN

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools